BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 27487959)

  • 1. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease.
    Arora P; Gupta A; Golzy M; Patel N; Carter RL; Jalal K; Lohr JW
    BMC Nephrol; 2016 Aug; 17(1):112. PubMed ID: 27487959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
    Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
    JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
    Hart E; Dunn TE; Feuerstein S; Jacobs DM
    Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.
    Wijarnpreecha K; Thongprayoon C; Chesdachai S; Panjawatanana P; Ungprasert P; Cheungpasitporn W
    Dig Dis Sci; 2017 Oct; 62(10):2821-2827. PubMed ID: 28836158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
    Xie Y; Bowe B; Li T; Xian H; Balasubramanian S; Al-Aly Z
    J Am Soc Nephrol; 2016 Oct; 27(10):3153-3163. PubMed ID: 27080976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPIs and kidney disease: from AIN to CKD.
    Moledina DG; Perazella MA
    J Nephrol; 2016 Oct; 29(5):611-6. PubMed ID: 27072818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Proton pump inhibitors and kidney].
    Desbuissons G; Deray G; Mercadal L
    Nephrol Ther; 2018 Apr; 14 Suppl 1():S115-S124. PubMed ID: 29274872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using proton pump inhibitors correlates with an increased risk of chronic kidney disease: a nationwide database-derived case-controlled study.
    Hung SC; Liao KF; Hung HC; Lin CL; Lai SW; Lee PC; Hung SR
    Fam Pract; 2018 Mar; 35(2):166-171. PubMed ID: 29045621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton pump inhibitor usage and the associated risk of pneumonia in patients with chronic kidney disease.
    Chen CH; Lin HC; Lin HL; Lin YT; Chou JM; Hsu SP; Fung CP
    J Microbiol Immunol Infect; 2015 Aug; 48(4):390-6. PubMed ID: 24291618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis.
    Grant CH; Gillis KA; Lees JS; Traynor JP; Mark PB; Stevens KI
    QJM; 2019 Nov; 112(11):835-840. PubMed ID: 31251364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease.
    Klatte DCF; Gasparini A; Xu H; de Deco P; Trevisan M; Johansson ALV; Wettermark B; Ärnlöv J; Janmaat CJ; Lindholm B; Dekker FW; Coresh J; Grams ME; Carrero JJ
    Gastroenterology; 2017 Sep; 153(3):702-710. PubMed ID: 28583827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence.
    Ben-Eltriki M; Green CJ; Maclure M; Musini V; Bassett KL; Wright JM
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00651. PubMed ID: 32996701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis.
    Nochaiwong S; Ruengorn C; Awiphan R; Koyratkoson K; Chaisai C; Noppakun K; Chongruksut W; Thavorn K
    Nephrol Dial Transplant; 2018 Feb; 33(2):331-342. PubMed ID: 28339835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study.
    Kim SG; Cho JM; Han K; Joo KW; Lee S; Kim Y; Cho S; Huh H; Kim M; Kang E; Kim DK; Park S
    BMJ Open; 2024 Jan; 14(1):e078032. PubMed ID: 38286693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury.
    Leonard CE; Freeman CP; Newcomb CW; Reese PP; Herlim M; Bilker WB; Hennessy S; Strom BL
    Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1155-72. PubMed ID: 22887960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study.
    Xie Y; Bowe B; Yan Y; Xian H; Li T; Al-Aly Z
    BMJ; 2019 May; 365():l1580. PubMed ID: 31147311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD-REIN cohort study.
    Liabeuf S; Lambert O; Metzger M; Hamroun A; Laville M; Laville SM; Frimat L; Pecoits-Filho R; Fouque D; Massy ZA; Jacquelinet C; Stengel B;
    Br J Clin Pharmacol; 2021 Jul; 87(7):2967-2976. PubMed ID: 33368448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demographic and health-related predictors of proton pump inhibitor (PPI) use and association with chronic kidney disease (CKD) stage in NHANES population.
    Devraj R; Deshpande M
    Res Social Adm Pharm; 2020 Jun; 16(6):776-782. PubMed ID: 31445985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort.
    Rodríguez-Poncelas A; Barceló MA; Saez M; Coll-de-Tuero G
    PLoS One; 2018; 13(10):e0204231. PubMed ID: 30332411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease.
    Hughes J; Y Y Chiu D; Kalra PA; Green D
    PLoS One; 2018; 13(5):e0197400. PubMed ID: 29799851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.